Skip to main content
Erschienen in: Clinical and Translational Oncology 9/2019

16.01.2019 | Research Article

The incidence proportion of erectile dysfunction in patients treated with cryotherapy for prostate cancer: a meta-analysis

verfasst von: J. T. Zhou, D. M. Fang, S. Xia, T. Li, R. L. Liu

Erschienen in: Clinical and Translational Oncology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

With the maturity of cryotherapy for prostate cancer, the complications after operation are also decreasing, which can improve the prognosis of patients. However, erectile dysfunction (ED) is still one of the main complications after cryotherapy. Therefore, we performed a meta-analysis to evaluate the incidence of erectile dysfunction in patients after cryotherapy.

Materials and methods

A comprehensive literature search was performed in August 2018. PUBMED and EMBASE databases were searched to collect studies reporting the incidence rate of ED after cryotherapy from 2002 to 2018. Two reviewers independently screened the literatures, extracted data and assessed the risk of bias of included studies. Pooled ratio and its 95% confidence intervals (95% CIs) were performed by Stata 12.1.

Results

Of the 157 articles identified on August 1st 2018, 23 studies which reported ED after cold ablative therapy were identified, however, only 12 used validated outcome measures and met inclusion criteria. A total of 12 studies were included in this meta-analysis. Overall, the results of this meta-analysis showed that the pooled incidence rate of ED was 0.27 (95% CI 0.26–0.28) which means that the incidence rate of ED after cryotherapy for prostate cancer was not high, but we still found that there are great heterogeneity between the 12 articles. By subgroup analysis, we found a statistically significant incidence rate of ED in primarily localized PCa which was 0.49 (95% CI 0.30–0.68), which is clearly lower than the incidence of recurrent prostate cancer after failed primary radiotherapy 0.61 (95% CI 0.43–0.79).

Conclusion

ED is one of the major complications after cryotherapy for PCa. Furthermore, subgroup analysis revealed a higher incidence rate in PCa undergoing radiotherapy. Significantly, with the development of cryotherapy technology, the incidence of ED after cryotherapy for prostate cancer is decreasing. While we still need further researches to advance knowledge in this field.
Literatur
1.
Zurück zum Zitat Boring CC, et al. Cancer statistics, 1994. CA Cancer J Clin. 2010;40(1):9–26. Boring CC, et al. Cancer statistics, 1994. CA Cancer J Clin. 2010;40(1):9–26.
2.
Zurück zum Zitat Lian H, et al. Cryosurgery as primary treatment for localized prostate cancer. Int Urol Nephrol. 2011;43(4):1089–94.CrossRefPubMed Lian H, et al. Cryosurgery as primary treatment for localized prostate cancer. Int Urol Nephrol. 2011;43(4):1089–94.CrossRefPubMed
3.
Zurück zum Zitat Cooperberg MR, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22(11):2141–9.CrossRefPubMedPubMedCentral Cooperberg MR, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22(11):2141–9.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Han M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169(2):517–23.CrossRefPubMed Han M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169(2):517–23.CrossRefPubMed
5.
Zurück zum Zitat Roach M, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000;47(3):609–15.CrossRefPubMed Roach M, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000;47(3):609–15.CrossRefPubMed
6.
Zurück zum Zitat Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002;54(4):1063–8.CrossRefPubMed Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002;54(4):1063–8.CrossRefPubMed
7.
Zurück zum Zitat Shah S, Young HN, Cobran EK. Comparative effectiveness of conservative management compared to cryotherapy in localized prostate cancer patients. Am J Men’s Health. 2018;12(5):1681–91.CrossRef Shah S, Young HN, Cobran EK. Comparative effectiveness of conservative management compared to cryotherapy in localized prostate cancer patients. Am J Men’s Health. 2018;12(5):1681–91.CrossRef
8.
Zurück zum Zitat Asterling S, Greene DR. Prospective evaluation of sexual function in patients receiving cryosurgery as a primary radical treatment for localized prostate cancer. BJU Int. 2009;103(6):788–92.CrossRefPubMed Asterling S, Greene DR. Prospective evaluation of sexual function in patients receiving cryosurgery as a primary radical treatment for localized prostate cancer. BJU Int. 2009;103(6):788–92.CrossRefPubMed
9.
Zurück zum Zitat Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int. 2012;109(11):1648–54.CrossRefPubMed Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int. 2012;109(11):1648–54.CrossRefPubMed
10.
Zurück zum Zitat Kim FJ, et al. Initial Brazilian experience in the treatment of localized prostate cancer using a new generation cryotechnology: feasibility study. Int Braz J Urol. 2012;38(5):620–6.CrossRefPubMed Kim FJ, et al. Initial Brazilian experience in the treatment of localized prostate cancer using a new generation cryotechnology: feasibility study. Int Braz J Urol. 2012;38(5):620–6.CrossRefPubMed
11.
Zurück zum Zitat Roberts CB, et al. Treatment profile and complications associated with cryotherapy for localized prostate cancer: a population-based study. Prostate Cancer Prostatic Dis. 2011;14(4):313–9.CrossRefPubMedPubMedCentral Roberts CB, et al. Treatment profile and complications associated with cryotherapy for localized prostate cancer: a population-based study. Prostate Cancer Prostatic Dis. 2011;14(4):313–9.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Anastasiadis AG, et al. Comparison of health-related quality of life and prostate-associated symptoms after primary and salvage cryotherapy for prostate cancer. J Cancer Res Clin Oncol. 2003;129(12):676–82.CrossRefPubMed Anastasiadis AG, et al. Comparison of health-related quality of life and prostate-associated symptoms after primary and salvage cryotherapy for prostate cancer. J Cancer Res Clin Oncol. 2003;129(12):676–82.CrossRefPubMed
13.
Zurück zum Zitat Gevorgyan A, et al. Cryothérapie prostatique de rattrapage après échec de radiothérapie externe ou curiethérapie: morbidité et résultats oncologiques à moyen terme. Progrès en Urologie. 2018;28(5):291–301.CrossRefPubMed Gevorgyan A, et al. Cryothérapie prostatique de rattrapage après échec de radiothérapie externe ou curiethérapie: morbidité et résultats oncologiques à moyen terme. Progrès en Urologie. 2018;28(5):291–301.CrossRefPubMed
14.
Zurück zum Zitat Ismail M, et al. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int. 2007;100(4):760–4.CrossRefPubMed Ismail M, et al. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int. 2007;100(4):760–4.CrossRefPubMed
15.
Zurück zum Zitat Philippou P, Yap T, Chinegwundoh F. Third-generation salvage cryotherapy for radiorecurrent prostate cancer: a centre’s experience. Urol Int. 2012;88(2):137–44.CrossRefPubMed Philippou P, Yap T, Chinegwundoh F. Third-generation salvage cryotherapy for radiorecurrent prostate cancer: a centre’s experience. Urol Int. 2012;88(2):137–44.CrossRefPubMed
16.
Zurück zum Zitat Ellis DS. Cryosurgery as primary treatment for localized prostate cancer: a community hospital experience. Urology. 2002;60(2 Suppl 1):34–9.CrossRefPubMed Ellis DS. Cryosurgery as primary treatment for localized prostate cancer: a community hospital experience. Urology. 2002;60(2 Suppl 1):34–9.CrossRefPubMed
17.
Zurück zum Zitat Barqawi A, et al. Prospective outcome analysis of the safety and efficacy of partial and complete cryoablation in organ-confined prostate cancer. Urology. 2018;112:126–31.CrossRefPubMed Barqawi A, et al. Prospective outcome analysis of the safety and efficacy of partial and complete cryoablation in organ-confined prostate cancer. Urology. 2018;112:126–31.CrossRefPubMed
18.
Zurück zum Zitat Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res. 2005;17(4):307–19.CrossRefPubMed Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res. 2005;17(4):307–19.CrossRefPubMed
19.
Zurück zum Zitat Rosen RC, Cappelleri JC, Gendrano N. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14(4):226–44.CrossRefPubMed Rosen RC, Cappelleri JC, Gendrano N. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14(4):226–44.CrossRefPubMed
20.
21.
Zurück zum Zitat Robinson JW, et al. Quality-of-life outcomes for men treated with cryosurgery for localized prostate carcinoma. Cancer. 1999;86(9):1793–801.CrossRefPubMed Robinson JW, et al. Quality-of-life outcomes for men treated with cryosurgery for localized prostate carcinoma. Cancer. 1999;86(9):1793–801.CrossRefPubMed
22.
Zurück zum Zitat Onik GM, et al. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer. 1993;72(4):1291–9.CrossRefPubMed Onik GM, et al. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer. 1993;72(4):1291–9.CrossRefPubMed
23.
Zurück zum Zitat Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psycho Oncol. 2002;11(4):307–26.CrossRef Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psycho Oncol. 2002;11(4):307–26.CrossRef
24.
Zurück zum Zitat Ponholzer A, et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol. 2005;47(1):80–6.CrossRefPubMed Ponholzer A, et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol. 2005;47(1):80–6.CrossRefPubMed
25.
Zurück zum Zitat Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMed Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMed
26.
Zurück zum Zitat Bax L, et al. More than numbers: the power of graphs in meta-analysis. Am J Epidemiol. 2008;169(2):249–55.CrossRefPubMed Bax L, et al. More than numbers: the power of graphs in meta-analysis. Am J Epidemiol. 2008;169(2):249–55.CrossRefPubMed
27.
Zurück zum Zitat Seagroatt V, Stratton I. Bias in meta-analysis detected by a simple, graphical test. Test had 10% false positive rate. BMJ. 1997;316(7129):469–471. Seagroatt V, Stratton I. Bias in meta-analysis detected by a simple, graphical test. Test had 10% false positive rate. BMJ. 1997;316(7129):469–471.
28.
Zurück zum Zitat Consensus development conference statement. National institutes of health. Impotence. December 7–9, 1992. Int J Impot Res. 1993;5(4):181–284. Consensus development conference statement. National institutes of health. Impotence. December 7–9, 1992. Int J Impot Res. 1993;5(4):181–284.
Metadaten
Titel
The incidence proportion of erectile dysfunction in patients treated with cryotherapy for prostate cancer: a meta-analysis
verfasst von
J. T. Zhou
D. M. Fang
S. Xia
T. Li
R. L. Liu
Publikationsdatum
16.01.2019
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 9/2019
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02036-8

Weitere Artikel der Ausgabe 9/2019

Clinical and Translational Oncology 9/2019 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.